Combivir And Maraviroc In Antiretroviral Naive Subjects In Russia
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
One hundred subjects in Russia will be treated with a combination of Combivir (zidovudine and
lamivudine) and maraviroc as their first line HIV therapy. The aim is to assess the efficacy
and safety of this combination in a Russian population of patients.
Phase:
Phase 4
Details
Lead Sponsor:
ViiV Healthcare
Collaborator:
Pfizer
Treatments:
Lamivudine Lamivudine, zidovudine drug combination Maraviroc Zidovudine